Terms: = Brain cancer AND ERBB3, c-erbB3, 2065, P21860, p180-ErbB3, c-erbB-3, ErbB-3, MDA-BF-1, HER3, p85-sErbB3, MGC88033, p45-sErbB3, ENSG00000065361, erbB3-S
89 results:
1. Phenotype analysis of families with TP53 germline variants at the Center for Familial Breast and Ovarian cancer, Cologne.
Kast K; Rhiem K; Larsen M; Wappenschmidt B; Schmutzler R
Cancer Med; 2024 Feb; 13(3):e6920. PubMed ID: 38230850
[TBL] [Abstract] [Full Text] [Related]
2. Targeted Hyperbranched Nanoparticles for Delivery of Doxorubicin in Breast cancer brain Metastasis.
Lim M; Fletcher NL; Saunus JM; McCart Reed AE; Chittoory H; Simpson PT; Thurecht KJ; Lakhani SR
Mol Pharm; 2023 Dec; 20(12):6169-6183. PubMed ID: 37970806
[TBL] [Abstract] [Full Text] [Related]
3. Systematic characterization of antibody-drug conjugate targets in central nervous system tumors.
Coy S; Lee JS; Chan SJ; Woo T; Jones J; Alexandrescu S; Wen PY; Sorger PK; Ligon KL; Santagata S
Neuro Oncol; 2024 Mar; 26(3):458-472. PubMed ID: 37870091
[TBL] [Abstract] [Full Text] [Related]
4. Association of the m
Li Y; Cao J; Wang J; Wu W; Jiang L; Sun X
Cancer; 2024 Feb; 130(3):356-374. PubMed ID: 37861451
[TBL] [Abstract] [Full Text] [Related]
5. HERTHENA-Lung01, a Phase II Trial of Patritumab Deruxtecan (her3-DXd) in Epidermal Growth Factor Receptor-Mutated Non-Small-Cell Lung cancer After Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy and Platinum-Based Chemotherapy.
Yu HA; Goto Y; Hayashi H; Felip E; Chih-Hsin Yang J; Reck M; Yoh K; Lee SH; Paz-Ares L; Besse B; Bironzo P; Kim DW; Johnson ML; Wu YL; John T; Kao S; Kozuki T; Massarelli E; Patel J; Smit E; Reckamp KL; Dong Q; Shrestha P; Fan PD; Patel P; Sporchia A; Sternberg DW; Sellami D; Jänne PA
J Clin Oncol; 2023 Dec; 41(35):5363-5375. PubMed ID: 37689979
[TBL] [Abstract] [Full Text] [Related]
6. Genomic analysis of plasma circulating tumor DNA in patients with heavily pretreated HER2 + metastatic breast cancer.
Lee K; Lee J; Choi J; Sim SH; Kim JE; Kim MH; Park YH; Kim JH; Koh SJ; Park KH; Kang MJ; Ahn MS; Lee KE; Kim HJ; Ahn HK; Kim HJ; Park KU; Park IH
Sci Rep; 2023 Jun; 13(1):9928. PubMed ID: 37336919
[TBL] [Abstract] [Full Text] [Related]
7. Keeping It in the Family: her3 as a Target in brain Metastases.
Kabraji S; Lin NU
Clin Cancer Res; 2023 Aug; 29(16):2961-2963. PubMed ID: 37306554
[TBL] [Abstract] [Full Text] [Related]
8. Frequent Overexpression of her3 in brain Metastases from Breast and Lung cancer.
Tomasich E; Steindl A; Paiato C; Hatziioannou T; Kleinberger M; Berchtold L; Puhr R; Hainfellner JA; Müllauer L; Widhalm G; Eckert F; Bartsch R; Heller G; Preusser M; Berghoff AS
Clin Cancer Res; 2023 Aug; 29(16):3225-3236. PubMed ID: 37036472
[TBL] [Abstract] [Full Text] [Related]
9. The Yin and Yang of ERBB4: Tumor Suppressor and Oncoprotein.
Lucas LM; Dwivedi V; Senfeld JI; Cullum RL; Mill CP; Piazza JT; Bryant IN; Cook LJ; Miller ST; Lott JH; Kelley CM; Knerr EL; Markham JA; Kaufmann DP; Jacobi MA; Shen J; Riese DJ
Pharmacol Rev; 2022 Jan; 74(1):18-47. PubMed ID: 34987087
[TBL] [Abstract] [Full Text] [Related]
10. erbb3 overexpression due to miR-205 inactivation confers sensitivity to FGF, metabolic activation, and liability to erbb3 targeting in glioblastoma.
De Bacco F; Orzan F; Erriquez J; Casanova E; Barault L; Albano R; D'Ambrosio A; Bigatto V; Reato G; Patanè M; Pollo B; Kuesters G; Dell'Aglio C; Casorzo L; Pellegatta S; Finocchiaro G; Comoglio PM; Boccaccio C
Cell Rep; 2021 Jul; 36(4):109455. PubMed ID: 34320350
[TBL] [Abstract] [Full Text] [Related]
11. Germline erbb3 mutation in familial non-small-cell lung carcinoma: expanding ErbB's role in oncogenesis.
McInerney-Leo AM; Chew HY; Inglis PL; Leo PJ; Joseph SR; Cooper CL; Okano S; Hassall T; Anderson LK; Bowman RV; Gattas M; Harris JE; Marshall MS; Shaw JG; Wheeler L; Yang IA; Brown MA; Fong KM; Simpson F; Duncan EL
Hum Mol Genet; 2021 Nov; 30(24):2393-2401. PubMed ID: 34274969
[TBL] [Abstract] [Full Text] [Related]
12. The expression and prognostic value of the epidermal growth factor receptor family in glioma.
Xu B; Huo Z; Huang H; Ji W; Bian Z; Jiao J; Sun J; Shao J
BMC Cancer; 2021 Apr; 21(1):451. PubMed ID: 33892666
[TBL] [Abstract] [Full Text] [Related]
13. A feed-forward loop between SorLA and her3 determines heregulin response and neratinib resistance.
Al-Akhrass H; Conway JRW; Poulsen ASA; Paatero I; Kaivola J; Padzik A; Andersen OM; Ivaska J
Oncogene; 2021 Feb; 40(7):1300-1317. PubMed ID: 33420373
[TBL] [Abstract] [Full Text] [Related]
14. mTOR kinase inhibition disrupts neuregulin 1-erbb3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Beauchamp RL; Erdin S; Witt L; Jordan JT; Plotkin SR; Gusella JF; Ramesh V
J Biol Chem; 2021; 296():100157. PubMed ID: 33273014
[TBL] [Abstract] [Full Text] [Related]
15. A structural view of PA2G4 isoforms with opposing functions in cancer.
Stevenson BW; Gorman MA; Koach J; Cheung BB; Marshall GM; Parker MW; Holien JK
J Biol Chem; 2020 Nov; 295(47):16100-16112. PubMed ID: 32952126
[TBL] [Abstract] [Full Text] [Related]
16. Circular HER2 RNA positive triple negative breast cancer is sensitive to Pertuzumab.
Li J; Ma M; Yang X; Zhang M; Luo J; Zhou H; Huang N; Xiao F; Lai B; Lv W; Zhang N
Mol Cancer; 2020 Sep; 19(1):142. PubMed ID: 32917240
[TBL] [Abstract] [Full Text] [Related]
17. The roles of multifunctional protein erbb3 binding protein 1 (EBP1) isoforms from development to disease.
Hwang I; Ko HR; Ahn JY
Exp Mol Med; 2020 Jul; 52(7):1039-1047. PubMed ID: 32719408
[TBL] [Abstract] [Full Text] [Related]
18. Cell Lineage-Based Stratification for Glioblastoma.
Wang Z; Sun D; Chen YJ; Xie X; Shi Y; Tabar V; Brennan CW; Bale TA; Jayewickreme CD; Laks DR; Alcantara Llaguno S; Parada LF
Cancer Cell; 2020 Sep; 38(3):366-379.e8. PubMed ID: 32649888
[TBL] [Abstract] [Full Text] [Related]
19. A pan-HER-targeted approach for recurrent or late-stage cervical cancer therapy: mechanisms, recent advances, and clinical prospects.
Liu Y; An Q; Zhao X
Eur Rev Med Pharmacol Sci; 2020 Apr; 24(8):4123-4131. PubMed ID: 32373948
[TBL] [Abstract] [Full Text] [Related]
20. The role of ErbB4 in cancer.
Segers VFM; Dugaucquier L; Feyen E; Shakeri H; De Keulenaer GW
Cell Oncol (Dordr); 2020 Jun; 43(3):335-352. PubMed ID: 32219702
[TBL] [Abstract] [Full Text] [Related]
[Next]
